A phase III trial of amitriptyline/ketamine in patients with chemotherapy-induced peripheral neuropathies who have previously received taxane-based chemotherapy.
Latest Information Update: 17 Apr 2014
Price :
$35 *
At a glance
- Drugs Amitriptyline/ketamine (Primary) ; Amitriptyline; Ketamine
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Sponsors Immune Pharmaceuticals Inc
- 10 Apr 2014 Planned initiation date changed from 1 Dec 2012 to unknown (licensing partner is being sought).
- 28 Dec 2011 Status changed from planning to not yet recruiting.
- 12 Nov 2010 New trial record